Un-audited financial results for the quarter ended 30-06-2025
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Samrat Pharmachem reported weak Q1 FY26 results with revenue from operations of Rs 7,565.16 lakhs, down about 6.4% from Rs 8,082.40 lakhs in the same quarter last year. Total income stood at Rs 7,634.29 lakhs while total expenses were nearly flat at Rs 7,613.51 lakhs, leaving a thin profit before tax of just Rs 20.78 lakhs versus Rs 281.85 lakhs a year ago. The company slipped into a net loss of Rs 22.89 lakhs (loss per share of Rs 0.74), compared to a profit of Rs 206.55 lakhs (EPS Rs 6.69) in Q1 FY25. The auditor (Shah & Savla LLP) issued an unqualified limited review report with no qualifications or emphasis of matter. The cost of materials consumed rose to Rs 8,251.71 lakhs from Rs 7,815.54 lakhs, indicating margin pressure despite lower revenue.
Negative for shareholders — the company swung from a healthy profit to a small loss YoY, with sharply compressed margins and declining revenue, which is likely to weigh on near-term stock sentiment.